このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Femasys マネジメント

マネジメント基準チェック /24

Femasys'の CEO はKathy Lee-Sepsickで、 Feb2004年に任命され、の在任期間は 20.33年です。の年間総報酬は$ 1.02Mで、 49%給与と51%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.58%を直接所有しており、その価値は$ 353.50K 。経営陣と取締役会の平均在任期間はそれぞれ2年と8.7年です。

主要情報

Kathy Lee-Sepsick

最高経営責任者

US$1.0m

報酬総額

CEO給与比率	49.0%
CEO在任期間	20.7yrs
CEOの所有権	1.6%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	9yrs

経営陣の近況

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Jul 05

Recent updates

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Jul 05

CEO報酬分析

Femasys の収益と比較して、Kathy Lee-Sepsick の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$1m	US$500k	-US$14m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$659k	US$423k	-US$11m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$567k	US$540k	-US$8m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$307k	US$280k	-US$7m

報酬と市場: Kathyの総報酬 ($USD 1.02M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Kathyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Kathy Lee-Sepsick (56 yo)

20.7yrs

在職期間

US$1,019,425

報酬

Ms. Kathy Lee-Sepsick M.B.A, is Founder of Femasys Inc. and has been its Chief Executive Officer and President since February 2004. She served as Chairman of Board of Femasys Inc. since February 2004 until...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kathy Lee-Sepsick	Founder	20.7yrs	US$1.02m	1.57% $ 388.5k
Dov Elefant	Chief Financial Officer	2.7yrs	US$716.22k	0% $ 0
Daniel Currie	COO, Senior VP & Secretary	20.8yrs	US$630.42k	0.40% $ 99.5k
Mary Merchant	Vice President of Counsel & Intellectual Property	no data	データなし	データなし
Sue Owens	Vice President of Sales	no data	データなし	データなし
Naomi Phaneuf	Vice President of Marketing	no data	データなし	データなし
Jeffrey Marcus	Chief Medical Advisor	no data	データなし	データなし
Christine Thomas	Senior VP of Regulatory & Clinical Affairs	2yrs	データなし	データなし
James Liu	Chief Medical Officer	less than a year	データなし	データなし
Richard Spector	Chief Commercial Officer	less than a year	データなし	データなし

2.3yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: FEMYの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Kathy Lee-Sepsick	Founder	20.7yrs	US$1.02m	1.57% $ 388.5k
Charles Larsen	Independent Non-Executive Chairman of Board	9yrs	US$108.93k	0.14% $ 34.9k
Joshua Silverman	Independent Director	less than a year	US$5.00k	データなし
Edward Uzialko	Independent Director	19.2yrs	US$41.97k	5.48% $ 1.4m
Alistair Milnes	Independent Director	1.3yrs	US$31.44k	0.025% $ 6.3k

9.0yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: FEMYの取締役会は経験豊富であると考えられます ( 8.7年の平均在任期間)。

Femasys マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Femasys Inc., Annual General Meeting, Jul 12, 2024

Femasys Inc. Appoints Richard Spector as Chief Commercial Officer

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. Appoints Joshua Silverman as Director

Femasys Inc. Designates Daniel Currie as its Chief Operating Officer

Recent updates

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check

Consensus revenue estimates fall by 40%

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Femasys Inc., Annual General Meeting, Jul 12, 2024

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target increased by 8.1% to US$10.00

New major risk - Financial position

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 13%

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

New major risk - Share price stability

Femasys Inc. Appoints Richard Spector as Chief Commercial Officer

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors

Femasys Inc. Appoints Joshua Silverman as Director

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

New major risk - Revenue and earnings growth

Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

New major risk - Revenue and earnings growth

Femasys Inc. Designates Daniel Currie as its Chief Operating Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women

Femasys Inc. Announces Management Changes

Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada

Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Femasys Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc.'s FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

Consensus EPS estimates fall by 32%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

Femasys Inc. Reports Encouraging Promotional Launch of Femcerv At AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

Femasys Inc. Completes Over 25% of its Targeted Enrollment in its FemaSeed De Novo Trial

Price target decreased to US$7.33

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Provides Strategic Update on FemaSeed Pivotal Trial Design to Expedite Clinical Program Advancement

Femasys Inc. Appoints Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs, Effective October 10, 2022

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

Femasys Inc. Announces Commercial Availability of FemCerv®

Femasys commercially launches Femcerv for cervical cancer screening

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Femasys Inc. Announces Board Changes

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Femasys Inc. Appoints Dov Elefant to Chief Financial Officer, Effective February 28, 2022

Insufficient new directors

Femasys: Revolutionizing Female Reproduction

Independent Director recently bought US$172k worth of stock

Femasys Inc. has completed an IPO in the amount of $34.45 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

マネジメント基準チェック /24